/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ( CSU ), Chronic Inducible Urticaria ( CIndU ) and asthma and we continue to consider additional indications in mast cell driven diseases for potential future development. We have also historically explored development programs in di…
$0.62
$0.02 (-2.56%)
EOD Sep 18, 2026
ROIC dropped from -83.24% to -192.43%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$32M
▼ -6.4% YoY
Op. Margin
—
ROIC
-711.50%
▼ -109.2pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$60M
▼ -23.3% YoY
Net Debt
-$7M
Net Cash Position
Cash & Equiv.
$7M
Continue Research
SourceComputed from the 10-Q filed 14 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 15 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.